Saturday 17 October 2026 Export GMAB’s income statement to Excel — free account

Genmab A/S Sponsored ADR

Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024. In the quarter to June 2026, revenue grew 24.9%, EPS fell 9.26% and free cash flow fell 7.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

37.00 0.82 −2.17%

Follow GMAB

Alert me

Market cap: $22.6B
P/E: 29.1×
Fwd P/E: 21.0×
Dividend yield: —
F-score: 4/9
Altman Z: 2.78
Beneish M: −3.00
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 4.28%

Capital & Financial Ratios $m

Market Cap 22,600.00

Revenue 4,131.00

Net Income 906.00

Free Cash Flow (6,347.00)

Net Debt 3,632.00

Current Ratio 2.46

Debt/Equity 0.86

P/E ratio 29.13

Fwd P/E 21.00

P/S ratio 5.49

P/B ratio 3.81

Past 5Y EPS Growth 6.58%

This Y EPS Growth (23.23%)

Next Y EPS Growth 46.34%

Next Y revenue growth 19.13%

Next 5Y EPS Growth 21.18%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 63.15%

10-year low 10-year high

P/S against its own 10 years 26.69%

10-year low 10-year high

P/B against its own 10 years 34.08%

10-year low 10-year high

EV/Sales against its own 10 years 37.70%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4,085	2,954	1,715	1,503
Receivables	718	937	1,152	1,280
Inventory	8	9	18	18
Other	—	—	—	—
	4,812	3,900	2,885	2,801

	2023	2024	2025	Q'26
Payables	—	—	—	—
ST’ Debt	—	—	273	294
Other	—	3	24	21
	361	744	1,427	1,140

Compound Annual Growth %

	10y	5y	3y
Sales	—	19.15%	21.64%
Cash Flow	—	3.77%	28.89%
Earnings	—	5.73%	7.19%
Book Value	—	14.82%	14.59%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	896	1,155	—	—	—
’25	715	925	1,022	1,058	3,720
’24	603	779	816	923	3,121
’23	411	613	693	675	2,392
’22	320	452	553	742	2,067
’21	256	320	366	407	1,349
’20	132	805	271	341	1,549

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3	51	—	—	—
’25	287	62	536	301	1,186
’24	219	219	299	389	1,126
’23	466	70	297	238	1,072
’22	89	133	254	78	554
’21	192	58	66	39	354
’20	324	(6)	817	(150)	986

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	48	—	—	—
’25	257	52	534	(6,927)	(6,084)
’24	215	215	292	346	1,055
’23	451	54	283	219	1,017
’22	80	123	244	17	509
’21	188	45	54	18	314
’20	315	(27)	808	(166)	939

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.08	0.49	—	—	—
’25	0.31	0.54	0.65	0.05	1.54
’24	0.29	0.31	0.29	0.85	1.76
’23	0.05	0.30	0.47	0.14	0.96
’22	0.11	0.41	0.53	0.12	1.15
’21	0.27	0.08	0.21	0.17	0.72
’20	0.06	0.76	0.13	0.14	1.12

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	9.23	16.21	12.10	14.48	16.24	30.10	26.19	27.74	19.85	17.24	Analyst estimates 2026–2028 Powerpack
	High	19.41	23.55	103.19	24.50	41.50	49.07	47.50	43.66	32.88	33.96
People
People	Employees	—	—	419	548	781	1,212	1,660	2,204	2,682	3,029
	Revenue/emp, $m	0.00	0.00	1.14	1.47	1.98	1.11	1.24	1.09	1.16	1.23
Income, $m
Income, $m	Revenue	258	381	479	804	1,549	1,349	2,067	2,392	3,121	3,720
	Gross margin, %	0.00	0.00	100.00	100.00	100.00	100.00	100.00	98.63	95.42	93.60
	EBT	160	171	255	429	904	634	996	818	1,326	1,204
	EBT margin, %	62.22	44.99	53.29	53.28	58.39	46.96	48.20	34.22	42.49	32.37
	Net income	168	0	255	429	904	634	996	818	1,326	1,204
	Depreciation	6	11	14	21	40	39	51	43	60	71
Per share, $
Per share, $	Revenue	0.43	0.62	0.78	1.28	2.38	2.06	3.16	3.66	4.86	5.99
	Earnings	2.81	2.92	0.38	0.52	1.12	0.73	1.16	0.97	1.77	1.55
	Cash flow	0.08	0.41	0.26	0.32	1.51	0.54	0.85	1.64	1.75	1.91
	Capex	0.00	0.00	(0.12)	(0.03)	(0.07)	(0.06)	(0.07)	(0.08)	(0.11)	(11.70)
	Free cash flow	0.08	0.41	0.14	0.29	1.44	0.48	0.78	1.56	1.64	(9.79)
	Book value	1.13	1.63	2.07	3.34	4.49	5.40	5.94	7.03	8.00	9.41
	Shares, m	604	619	613	630	652	654	654	653	642	622
Valuation, ×
Valuation, ×	P/E	6.11	2.99	7.73	33.54	36.96	53.46	36.47	33.10	11.79	19.87
	P/S	0.00	0.00	0.00	17.48	17.11	19.17	13.61	8.77	4.29	5.15
	P/B	0.81	0.81	0.81	6.68	9.05	7.33	7.24	4.57	2.61	3.27
	EV/Sales	0.00	0.00	0.00	15.47	15.55	16.94	12.13	7.11	3.38	6.10
	EV/FCF	0.00	0.00	0.00	34.61	25.89	77.35	55.29	17.66	9.88	(3.73)
Cash, $m
Cash, $m	Operating cash flow	47	256	161	199	986	354	554	1,072	1,126	1,186
	Capex	(5)	(14)	(76)	(17)	(47)	(40)	(45)	(55)	(71)	(7,270)
	Free cash flow	47	256	85	182	939	314	509	1,017	1,055	(6,084)
Balance, $m
Balance, $m	Working capital	636	923	1,107	1,952	2,687	3,368	3,760	4,451	3,156	1,458
	Total debt	—	—	—	27	53	65	86	—	—	5,274
	Net debt	(556)	(873)	(967)	(1,617)	(2,411)	(3,012)	(3,075)	(4,085)	(2,954)	3,559
	Shareholders’ equity	685	1,010	1,269	2,106	2,929	3,531	3,886	4,590	5,137	5,847
Returns, %
Returns, %	ROA	18.64	47.86	22.39	17.99	26.46	13.37	19.06	13.43	19.64	9.99
	ROIC	0.00	0.00	45.21	50.60	116.54	57.78	69.44	95.70	27.83	7.08
	ROE	19.87	20.98	20.46	19.24	28.95	14.81	21.08	14.91	23.30	17.53

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RPRX Royalty Pharma PLC	$34.3B	42.3×	21.9×	+16.50% (above 0%: growing)	−40.00% (below 0%: shrinking)	+31.57% (above 0%: growing)	100.00%	19.75%	Compare
ALNY Alnylam Pharmaceuticals, Inc.	$31.3B	39.5×	39.6×	+66.86% (above 0%: growing)	n/m	+152.82% (above 0%: growing)	76.88%	17.93%	Compare
ROIV Roivant Sciences Ltd.	$24.6B	— (loss-making)	— (loss-making)	−33.55% (below 0%: shrinking)	n/m	−29.99% (below 0%: shrinking)	80.31%	(25,380.93%)	Compare
INCY Incyte Corporation	$23.0B	13.9×	15.6×	+37.72% (above 0%: growing)	+39.71% (above 0%: growing)	+1,829.52% (above 0%: growing)	93.73%	41.69%	Compare
BNTX BioNTech SE Sponsored ADR	$22.7B	— (loss-making)	— (loss-making)	−58.53% (below 0%: shrinking)	n/m	−342.04% (below 0%: shrinking)	8.14%	(897.82%)	Compare
GMAB Genmab A/S Sponsored ADR	$22.6B	29.1×	21.0×	+24.86% (above 0%: growing)	−9.26% (below 0%: shrinking)	−7.69% (below 0%: shrinking)	92.73%	32.47%
INSM Insmed, Inc.	$21.7B	— (loss-making)	— (loss-making)	+296.11% (above 0%: growing)	n/m	+54.52% (above 0%: growing)	84.20%	(0.36%)	Compare
EXEL Exelixis, Inc.	$15.6B	18.8×	16.7×	+10.63% (above 0%: growing)	+25.00% (above 0%: growing)	+557.25% (above 0%: growing)	96.71%	39.51%	Compare
ASND Ascendis Pharma A/S	$14.9B	16.3×	13.0×	+119.88% (above 0%: growing)	n/m	+2,335.93% (above 0%: growing)	91.85%	64.98%	Compare
Median of peers	$22.8B	18.8×	16.7×	+27.11%	+25.00%	+103.67%	88.03%	18.84%

All 614 Biotechnology stocks →

Genmab A/S Sponsored ADR (GMAB) key facts

Strength: Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
Genmab A/S Sponsored ADR (GMAB) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, GMAB traded at $37.00, a market capitalization of $22.6 billion.
Return on equity was 17.5% and debt-to-equity 0.86.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 2.78 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.